|
Korean treatment recommendations for patients with axial spondyloarthritis
Mi Ryoung Seo, Jina Yeo, Jun Won Park, Yeon-Ah Lee, Ju Ho Lee, Eun Ha Kang, Seon Mi Ji, Seong-Ryul Kwon, Seong-Kyu Kim, Tae-Jong Kim, Tae-Hwan Kim, Hye Won Kim, Min-Chan Park, Kichul Shin, Sang-Hoon Lee, Eun Young Lee, Hoon Suk Cha, Seung Cheol Shim, Youngim Yoon, Seung Ho Lee, Jun Hong Lim, Han Joo Baek; on behalf of the Korean Society of Spondyloarthritis Research
Korean J Intern Med. 2024;39(1):200-200. Published online November 10, 2023
|
|
|
Korean treatment recommendations for patients with axial spondyloarthritis
[corrected-article]
Mi Ryoung Seo, Jina Yeo, Jun Won Park, Yeon-Ah Lee, Ju Ho Lee, Eun Ha Kang, Seon Mi Ji, Seong-Ryul Kwon, Seong-Kyu Kim, Tae-Jong Kim, Tae-Hwan Kim, Hye Won Kim, Min-Chan Park, Kichul Shin, Sang-Hoon Lee, Eun Young Lee, Hoon Suk Cha, Seung Cheol Shim, Youngim Yoon, Seung Ho Lee, Jun Hong Lim, Han Joo Baek; on behalf of the Korean Society of Spondyloarthritis Research
Korean J Intern Med. 2023;38(5):620-640. Published online July 24, 2023
We aimed to develop evidence-based recommendations for treating axial spondylarthritis (axSpA) in Korea. The development committee was constructed, key clinical questions were determined, and the evidence was searched through online databases including MEDLINE, Embase, Cochrane, KoreaMed, and Kmbase..
|
|
|
Rheumatology
Comparative effectiveness of JAK inhibitors and biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
Soo-Kyung Cho, Hyoungyoung Kim, Yeo-Jin Song, Hye Won Kim, Eunwoo Nam, Shin-Seok Lee, Hye-Soon Lee, Sung-Hoon Park, Yeon-Ah Lee, Min-Chan Park, Sung Hae Chang, Hyoun-Ah Kim, Seung-Ki Kwok, Hae-Rim Kim, Hyun-Sook Kim, Bo Young Yoon, Wan-Sik Uhm, Yong-Gil Kim, Jae Hoon Kim, Jisoo Lee, Jeongim Choi, Yoon-Kyoung Sung
Korean J Intern Med. 2023;38(4):546-556. Published online June 20, 2023
Background/Aims: We aimed to compare the effectiveness and safety of Janus kinase inhibitors (JAKi) vs. biologic disease- modifying antirheumatic drugs (bDMARD) in Korean patients with rheumatoid arthritis (RA) who had an inadequate response to conventional synthetic DMARDs.
Methods: A quasi-exper..
|
|
|
Rapid onset of efficacy predicts response to therapy with certolizumab plus methotrexate in patients with active rheumatoid arthritis
Young Mo Kang, Young-Eun Park, Won Park, Jung-Yoon Choe, Chul-Soo Cho, Seung-Cheol Shim, Sang Cheol Bae, Chang-Hee Suh, Hoon-Suk Cha, Eun Mi Koh, Yeong-Wook Song, Bin Yoo, Shin-Seok Lee, Min-Chan Park, Sang-Heon Lee, Catherine Arendt, Willem Koetse, Soo-Kon Lee
Korean J Intern Med. 2018;33(6):1224-1233. Published online January 5, 2018
Background/Aims: The objective of this study was to determine the efficacy and safety of add-on therapy with certolizumab pegol (CZP) in active rheumatoid arthritis (RA) patients of a single ethnicity.
Methods: In this 24-week, phase 3, randomized, double-blind, placebo-controlled trial, eligible p..
|
|
|
